Bio Green Med Solution, Inc. (BGMS): Nasdaq/NYSE listing notice — Cyclacel receives Nasdaq notice for non-compliance with $1.00 bid price rule

Bio Green Med Solution, Inc.

Nasdaq notified Cyclacel on Jan 4, 2023 that common stock bid price below $1.00 for 30 consecutive days.
Company has 180 calendar days, until July 3, 2023, to regain compliance by closing at $1.00 for 10 consecutive days.
If not compliant, Nasdaq may delist; company may appeal or consider a reverse stock split.
No immediate effect on trading; shares continue on Nasdaq under symbol CYCC.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Bio Green Med Solution, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

January 4, 2023, Cyclacel Pharmaceuticals, Inc. (the “Company”) received a written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon the closing bid price of the Company’s common stock, par value $0.001 per share, (the “Common Stock”) for the last 30 consecutive business days, the Common Stock did not meet the minimum bid price of $1.00 per share required by Nasdaq Listing Rule 5550(a)(2), initiating an automatic 180 calendar-day grace period for the Company to regain compliance. The notice has no immediate effect on the listing or trading of the Company

View on SEC.gov

Browse all listing & compliance notices →

Bio Green Med Solution, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-001861

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.